People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ACEA Therapeutics, Inc. | — | Pharmaceuticals | Series B | $25.9M | $612.1M | 2018 |
| Northann Corp. | — | Other | Pre-Seed | $500K | $5.1M | 2022 |
Lin Li at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lin Li on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kurtis Weston Winn | 1 | 1 |
| Xiao Xu | 1 | 1 |
| Joyce Hsu | 1 | 1 |
| Jixun Lin | 1 | 1 |
| Ng Chi Keung | 1 | 1 |
| Mang Yu | 1 | 1 |
| Stephen Lin | 1 | 1 |
| Feng Lin | 1 | 1 |
| Xiaobo Wang | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.